Inhibitex to Present at the Canaccord Genuity 30th Annual Growth Conference on Thursday, August 12th
August 10 2010 - 2:37PM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H.
Plumb, president and chief executive officer, will present an
overview of the company and its pipeline of differentiated
antiviral compounds at the Canaccord Genuity 30th Annual Growth
Conference on Thursday, August 12, 2010 at 8:00 a.m. EDT. The
conference is being held at The Intercontinental Hotel in Boston,
Massachusetts. The presentation will be simultaneously webcast and
can be accessed by visiting the Investors section of the Inhibitex
website at www.inhibitex.com. Shortly following the live
webcast a replay will also be available on the Company website.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on developing products to prevent
and treat serious infectious diseases. The Company’s pipeline
includes FV-100, which is in Phase II clinical development for the
treatment of shingles, and INX-189, a nucleotide polymerase
inhibitor in development for the treatment of chronic hepatitis C
infections. The Company also has additional HCV nucleotide
polymerase inhibitors in preclinical development and has licensed
the use of its proprietary MSCRAMM® protein platform to Pfizer for
the development of staphylococcal vaccines.
For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024